A Real-world Study of Liposomal Irinotecan (Onivyde)-Based Therapy in Patients With Locally Advanced/Metastatic Pancreatic Cancer in China

NCT07026123 · clinicaltrials.gov ↗

NOT_YET_RECRUITING

Status

40

Enrollment

OTHER

Sponsor class

Conditions

Advanced Pancreatic Cancer

Interventions

DRUG: Nal-IRI (Onivyde®)-based treatment
DRUG: Other second-line treatment

Sponsor

RenJi Hospital

Collaborators

[object Object]